Table 4 Association between preclinical AD stages and conversion to MCI/DAT
From: Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition
Neuronal injury marker | Percentage of subjects in each category | Total number of subjects (Subjects who progressed) | Hazard ratio (95% CI) | p-value |
|---|---|---|---|---|
Combined-NI | Stage 0: 31.9% | 76 (7) | Ref. | Ref. |
Stage 1: 15.1% | 36 (5) | 2.6 (0.8-8.6) | 0.12 | |
Stage 2: 21.8% | 52 (6) | 1.8 (0.5-6.3) | 0.34 | |
Stage 3: 3.4% | 8 (2) | 11.3 (1.9-66.9) | 0.0072 | |
SNAP: 22.7% | 54 (8) | 2.4 (0.8-6.9) | 0.12 | |
SCINIB: 5.0% | 12 (2) | 4.9 (0.8-29.1) | 0.078 |